{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T13:44:31Z","timestamp":1768743871841,"version":"3.49.0"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,6,1]]},"DOI":"10.2169\/internalmedicine.8213-21","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T22:09:41Z","timestamp":1637359781000},"page":"1727-1730","source":"Crossref","is-referenced-by-count":3,"title":["The 30-year Natural History of Non-classic Fabry Disease with an R112H Mutation"],"prefix":"10.2169","volume":"61","author":[{"given":"Reiko","family":"Muto","sequence":"first","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Chutoen General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritoshi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Akahori","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Chutoen General Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hopkin RJ, Banikazemi M, Clarke L, et al. Caracterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res 5: 550-555, 2008.","DOI":"10.1203\/PDR.0b013e318183f132"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 81: 122-138, 2002.","DOI":"10.1097\/00005792-200203000-00003"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Svarstad E, Marti HP. The changing landscape of Fabry disease. Clin J Am Soc Nephrol 15: 569-576, 2020.","DOI":"10.2215\/CJN.09480819"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Eng CM, Desnick RJ. Molecular basis of Fabry disease: mutations and polymorphisms in the human \u03b1-galactosidase A gene. Hum Mutat 3: 103-111, 1994.","DOI":"10.1002\/humu.1380030204"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sakuraba H, Tsukimura T, Togawa T, et al. Fabry disease in a Japanese population-molecular and biochemical characteristics. Mol Genet Metab Rep 26: 73-79, 2018.","DOI":"10.1016\/j.ymgmr.2018.10.004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nishida M, Kosaka K, Hasegawa K, et al. A case of Fabry nephropathy with histological features of oligonephropathy. Eur J Pediatr 173: 1111-1114, 2014.","DOI":"10.1007\/s00431-013-2118-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yamashita S, Saotome M, Satoh H, et al. Plasma globotriaosylsphingosine level as a primary screening target for Fabry disease in patients with left ventricular hypertrophy. Circ J 83: 1901-1907, 2019.","DOI":"10.1253\/circj.CJ-19-0110"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Modrego A, Amaranto M, Godino A, Mendoza R, Barra JL, Corchero JL. Human \u03b1-galactosidase A mutants: priceless tools to develop novel therapies for Fabry disease. Ing J Mol Sci 22: 6518, 2021.","DOI":"10.3390\/ijms22126518"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sueoka H, Ichihara J, Tsukimura T, Togawa T, Sakuraba H. Nano-LC-MS\/MS for quantification of lyso-Gb3 and its analogues reveals a useful biomarker for Fabry disease. PloS One 10: e-127048, 2015.","DOI":"10.1371\/journal.pone.0127048"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E. Current and investigational therapeutics for Fabry disease. Kidney Int Rep 5: 407-413, 2019.","DOI":"10.1016\/j.ekir.2019.11.013"},{"key":"11","unstructured":"11. Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from randomized phase III ATTRACT study. J Med Genet 54: 288-296, 2017."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lenders M, Stappers F, Niemietz C, et al. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. J Med Genet 56: 548-556, 2019.","DOI":"10.1136\/jmedgenet-2019-106005"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/11\/61_8213-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T03:31:38Z","timestamp":1654313498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/11\/61_8213-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8213-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"article-number":"8213-21"}}